2009

/Tag:2009

Oramed’s Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.

JERUSALEM, Israel, December 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of alternative drug delivery systems, announced today that Dr Roy Eldor will present an overview of the clinical development of Oramed's Oral Insulin capsule. Dr. Eldor is the [...]

2018-05-30T17:05:01+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society’s Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; https://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the [...]

2018-05-30T17:05:02+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society’s Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)

JERUSALEM, October 20 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; https://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the [...]

2018-05-30T17:05:02+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference

JERUSALEM, September 3 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (https://www.oramed.com), a developer of alternative drug delivery systems, announced today that Nadav Kidron, its Chief Executive Officer, is scheduled to present at the Rodman & Renshaw's 11th Annual Healthcare Conference on Friday September 11, [...]

2018-05-30T17:05:03+00:00 Categories: Press Releases|Tags: |

Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award

JERUSALEM, August 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of oral delivery systems, today announced that it is the recipient of the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award. Oramed Pharmaceuticals is developing a platform technology to [...]

2018-05-30T17:05:03+00:00 Categories: Press Releases|Tags: |

Oramed’s Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England

JERUSALEM, August 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) (https://www.oramed.com), a developer of alternative drug delivery systems, announced today that Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D. was chosen to present an overview of the clinical development of Oramed's Oral Insulin capsule at Science@BPC [...]

2018-05-30T17:05:03+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

JERUSALEM, Israel, August 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) ( https://www.oramed.com), a developer of oral delivery systems, today reported that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a total net amount of NIS 3.1 million ($828,000), [...]

2018-05-30T17:05:04+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( https://www.oramed.com), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study [...]

2018-05-30T17:05:04+00:00 Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009

JERUSALEM, June 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (https://www.oramed.com), a developer of oral delivery systems, announced that Oramed was chosen to present at the 8th National Life Science & Technology Week ILSI-BIOMED Conference, Israel 2009. The presentation will be given by Mr. Nadav [...]

2018-05-30T17:05:04+00:00 Categories: Press Releases|Tags: |